ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag policy drug development industry academia

Industry vs Academia
The Scientist Staff | Apr 15, 2001 | 10+ min read
To conduct this survey, The Scientist invited 1800 readers via E-mail to respond to a web-based survey form. There were a total of 220 responses from March 2 to 12, 2001, a response rate of 12.2%. Have you held research positions in both academia and industry? (Positions may include graduate research, industrial internships, or any other research positions - paid or unpaid - in both work environments).   Percent Count Answers 72.6% 159/219 Yes 27.4% 60/219 No
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Best Places to Work Academia, 2012
The Scientist | Aug 1, 2012 | 9 min read
On the 10th anniversary of The Scientist’s survey of life science academics, institutions are contending with tighter budgets and larger administrative staffs, while working to sustain and inspire their researchers.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Minding the Drug Development Gap
Edward Spack | Nov 6, 2005 | 6 min read
Twenty-five years after the enactment of the Bayh-Dole Act, scientists and administrators in academia who are interested in moving bench discoveries to the clinic are learning what travelers in London's subway system already know: It's important to "mind the gap."
Tag, You're It
Carina Storrs | Feb 1, 2014 | 7 min read
A guide to DNA-encoded libraries for drug discovery
Opinion: Bias Is Unavoidable
Lisa Cosgrove | Aug 7, 2012 | 4 min read
Simply disclosing conflicts of interest is not enough.
Life Sciences Salary Survey 2011
Jef Akst and Edyta Zielinska | Dec 1, 2011 | 10+ min read
US salaries are starting to recover after last year’s survey recorded the first-ever drop.
Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
When Big Pharma Courts Academia
Joseph Paone | Jan 20, 2002 | 6 min read
Norman Greenberg tests AstraZeneca compounds on mice he genetically engineered to develop prostate cancer. He supplies the animals and the system for verifying the effectiveness of chemotherapy treatments while the company provides the compounds and testing costs, and gives Greenberg ample opportunity to prove just how well his system works. Together, the scientist from Baylor College of Medicine in Houston and his corporate partner warily straddle the barrier between academia and industry, and

Run a Search

ADVERTISEMENT